The molecule is only the first export
Much of the discussion around Chinese oncology innovation focuses on individual medicines: a promising ADC, another bispecific antibody, a positive Phase III readout or a major licensing agreement. But looking at these developments one at a time can obscure what is happening in clinical practice, where several new treatments may be competing for the same patients. Extensive-stage small-cell lung cancer provides a good example. For around three decades, platinum–etoposide was the standard first-line treatment. The introduction of immunotherapy began to change that from 2019, initially with atezolizumab and durvalumab. China has since developed several alternatives, including serplulimab, adebrelimab, tislelizumab and toripalimab. Ipsos’ Global Oncology Monitor data gives an interesting picture of how this competition is now playing out. Among first-line ES-SCLC regimens given to reported patients in China, the proportion containing immunotherapy increased from 55% in H1 2025 to 68% in H1 2026. Over the same period, the prescribing of regimens without immunotherapy declined from 45% to 32%. China-originated immunotherapies accounted for 44% of all reported first-line regimens in H1 2026, compared with 41% a year earlier but the share of Europe/US-originated immunotherapy composition also increased from 14% to 22%, while cross-border regimens represented a further 2%.
Fig 2: % of reported 1st line ES-SCLC regimens and region they originate from
This is what makes China particularly interesting to watch. The country is not simply producing more oncology medicines. It is creating a competitive environment in which several treatments can establish themselves within a relatively short period. As more Chinese-developed assets seek approval internationally, European companies may find themselves competing with several alternatives in the same indication, rather than one new entrant at a time. Looking beyond SCLC, China's wider immuno-oncology market also reminds us that clinical success does not guarantee commercial success. Keytruda and Opdivo helped transform cancer treatment globally, yet China's reimbursement policies and the availability of lower-priced domestic alternatives have created a very different competitive picture. When looking at prescribing data, it is worth understanding not only which treatments physicians favour, but also which ones their patients can realistically access. For companies developing or licensing Chinese assets, understanding these differences early may be just as important as understanding the clinical results themselves.
